Organovo Holdings Future Growth

Future criteria checks 2/6

Organovo Holdings's earnings are forecast to decline at 4.3% per annum while its annual revenue is expected to grow at 52% per year. EPS is expected to grow by 23.6% per annum.

Key information

-4.3%

Earnings growth rate

23.6%

EPS growth rate

Biotechs earnings growth	35.4%
Revenue growth rate	52.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	06 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:4OR1 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2026	0	-15	N/A	N/A	1
3/31/2025	0	-15	N/A	N/A	1
6/30/2024	0	-14	-12	-12	N/A
3/31/2024	0	-15	-15	-15	N/A
12/31/2023	0	-19	-17	-17	N/A
9/30/2023	0	-19	-16	-16	N/A
6/30/2023	0	-18	-16	-15	N/A
3/31/2023	0	-17	-13	-12	N/A
12/31/2022	2	-12	-10	-9	N/A
9/30/2022	2	-12	-10	-10	N/A
6/30/2022	2	-12	-10	-9	N/A
3/31/2022	2	-11	-9	-8	N/A
12/31/2021	N/A	-12	-9	-9	N/A
9/30/2021	N/A	-11	-8	-7	N/A
6/30/2021	N/A	-17	-13	-12	N/A
3/31/2021	N/A	-17	-14	-13	N/A
12/31/2020	N/A	-17	-15	-14	N/A
9/30/2020	0	-18	-14	-14	N/A
6/30/2020	2	-15	-12	-12	N/A
3/31/2020	2	-19	-15	-15	N/A
12/31/2019	3	-23	-17	-17	N/A
9/30/2019	3	-26	-20	-20	N/A
6/30/2019	3	-26	-19	-19	N/A
3/31/2019	3	-27	-20	-20	N/A
12/31/2018	4	-27	-21	-21	N/A
9/30/2018	4	-28	-24	-23	N/A
6/30/2018	4	-32	-25	-25	N/A
3/31/2018	5	-35	N/A	-29	N/A
12/31/2017	4	-38	N/A	-30	N/A
9/30/2017	4	-40	N/A	-31	N/A
6/30/2017	4	-40	N/A	-31	N/A
3/31/2017	4	-38	N/A	-29	N/A
12/31/2016	4	-36	N/A	-29	N/A
9/30/2016	3	-37	N/A	-29	N/A
6/30/2016	2	-39	N/A	-32	N/A
3/31/2016	1	-39	N/A	-29	N/A
12/31/2015	1	-38	N/A	-27	N/A
9/30/2015	1	-35	N/A	-25	N/A
6/30/2015	1	-32	N/A	-23	N/A
3/31/2015	1	-30	N/A	-20	N/A
12/31/2014	0	-29	N/A	-19	N/A
9/30/2014	0	-27	N/A	-19	N/A
6/30/2014	0	-29	N/A	-16	N/A
3/31/2014	0	-26	N/A	-16	N/A
12/31/2013	0	-35	N/A	-13	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4OR1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4OR1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4OR1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 4OR1's revenue (52% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: 4OR1's revenue (52% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4OR1's Return on Equity is forecast to be high in 3 years time

Organovo Holdings Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

New major risk - Financial position

First quarter 2025 earnings released: US$0.23 loss per share (vs US$0.46 loss in 1Q 2024)

Organovo Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Full year 2024 earnings released: US$1.60 loss per share (vs US$1.98 loss in FY 2023)

Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Third quarter 2024 earnings released: US$0.40 loss per share (vs US$0.38 loss in 3Q 2023)

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.605728 million.

Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings

New minor risk - Shareholder dilution

New major risk - Market cap size

Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results

New major risk - Market cap size

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Holdings, Inc. announced delayed annual 10-K filing

High number of new and inexperienced directors

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease

High number of new and inexperienced directors

BICO Reaches Beneficial and Sustainable Solution with Organovo

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

Organovo Holdings, Inc. Guides on Patent Portfolio and Successful IPR Defense of Two Patents

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

High number of new and inexperienced directors

Organovo Holdings, Inc. Enter into Two Lease Agreements Between Company and San Diego Inspire 1, LLC

Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Growth Index

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies